Tetra Bio-Pharma Announces Employment Contract Renewal of CEO Guy Chamberland
OTTAWA, April 01, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), today announced that the Company has renewed its CEO Guy Chamberland’s employment agreement.
We are extremely pleased with the progress that Guy has made since joining the company in 2016 and especially impressed with his accomplishments since being named CEO. Tetra is in the enviable position of having one of the most advanced pipeline of cannabinoid-based drug candidates in North America, working with Health Canada and the FDA, on clinical trial programs with cannabinoid-derived medicines
stated Tetra Bio-Pharma’s Chairman of the Board, Bill Cheliak.
It is for these reasons that the Board unanimously voted to renew Guy’s contract. The next few years are critical in the master planning for Tetra and the board reiterates its trust in Guy, who will lead his team through this process, focusing on building for the future and creating shareholder value
I am very excited to renew my engagement as CEO of Tetra Bio-Pharma. Over the last year we have accomplished a number of significant milestones and set the Company on track to bring a number of products forward.
First, we have built a strong team to bring a deep pipeline of cannabis drug products to commercialization.
Second, our pipeline is among the most advanced in the industry and we will advance those products on a global basis over the next year.
For example, just last week it was announced that we are finalizing the submission of a pre-marketing application for the registration of our cannabis drug PPP001 under Directive 2001/83/EC of the European Parliament. This European submission marks yet another major milestone for the Advanced Cancer program and the PPP001 medication. It is an important step towards providing the PPP001 new treatment option to cancer patients globally
stated Guy Chamberland, CEO of Tetra Bio-Pharma.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada authorized, and FDA reviewed, clinical trials aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of PPP001, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.